Cargando…

吉非替尼可能通过EGFR启动子甲基化诱导肺腺癌细胞继发性耐药

BACKGROUND AND OBJECTIVE: Nowadays the secondary resistance of gefitinib in the treatment of lung adenocarcinoma is an outstanding problem. This research is to explore whether the gefitinib secondary resistance can be induced by gefitinib, to explore whether epidermal growth factor receptor (EGFR) p...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000283/
https://www.ncbi.nlm.nih.gov/pubmed/25936882
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.04.04